Introduction: Cytochromes P450 (CYPs) are the major family of enzymes responsible for detoxification and metabolism of a wide range of both endogenous and xenobiotics chemicals in living organisms. The use of CYPs to activate prodrugs to cytotoxins selectively in tumours has been explored including AQ4N, Phortress and Aminoflavone. CYP1A1, CYP1B1, CYP2W1, and CYP4F11 have been identified as expressed in tumour tissue and surrounding stroma at high frequency compared to most normal tissues. Aim is to investigate the differential metabolism of novel chloromethylindoline by high frequency expressed CYPs in tumours. This differential may be exploited to elicit a selective chemotherapeutic effect by metabolising inert small molecules to potent cytotoxins within the tumour environment. Materials and Methods: Sensitive and specific LC/MS/MS techniques have been developed to investigate the metabolism of chloromethylindolines. Recombinant enzymes and transfected cell lines were used to investigate the metabolic profiles with a focus on production of the cytotoxic derivatives of chloromethylindolines. Results: Detailed metabolic studies show that (1-(Chloromethyl)-1,2-dihydropyrrolo [3,2-e]indol-3(6H)-yl)(5-methoxy-1H-indol-2-yl) methanone (ICT2700) and other chloromethylindolines are converted by CYP1A1 mediated hydroxylation at the C-5 position leading to highly potent metabolites. In vitro cytotoxicity studies showed differentials of up to 1000-fold was achieved between CYP1A1 activated compared to the non-metabolised parent molecules. The reactivity of metabolites of ICT2700 was also explored using glutathione as a nucleophile. The metabolites were identified by a combination of LC/MS and LC MS/MS techniques. Investigations using mouse and human liver microsomes show that a large number of metabolites are created though none were shown to be associated with a potential anticancer effect. Studies focused on CYP2W1 show that this isoform metabolised ICT2706 to a cytotoxic species and a pharmacokinetic study showed a good distribution of ICT2706 into mouse tissues including tumour. However metabolism of ICT2726 by CYP2W1 resulted only in a non-toxic metabolite profile and may have potential as a biomarker for functional CYP2W1 in tissues. Preliminary studies show that palmitic acid hydroxylation is a useful marker of functional CYP4F11. Summary and conclusion: The in vitro results show that the chloromethylindolines are a novel class of agent with potential as prodrugs that following specific hydroxylation by CYP1A1 and CYP2W1 are converted to ultra-potent cytotoxins. Other metabolites are also evident which are not cytotoxic. Studies in vivo show that selected chloromethylindolines possess a good pharmacokinetic profile and show potential as prodrug anticancer agents that require activation by CYP1A1 or CYP2W1. The methods, results, progress and suggestions for future work are presented in this thesis.

La variabilité interindividuelle dans la réponse aux médicaments constitue une problématique importante pouvant causer des effets indésirables ou l’échec d’un traitement. Ces variabilités peuvent être causées par une diminution de l’activité de l’enzyme responsable du métabolisme de certains médicaments, fréquemment les cytochromes P450, un système enzymatique majeur dans le métabolisme de ces derniers. Ces enzymes sont sujets à des mutations génétiques appelées polymorphismes, qui altèrent l’activité métabolique. Il est donc important d’évaluer le rôle de ces enzymes dans le métabolisme des médicaments afin d’identifier leur responsabilité dans la variabilité interindividuelle de la réponse au traitement. Parmi l’important système enzymatique que représentent les cytochromes P450, l’isoenzyme CYP2D6 est particulièrement étudiée, ses variations métaboliques revêtant une haute importance clinique. L’un des substrats du CYP2D6 est l’oxycodone, un analgésique narcotique largement prescrit en clinique. Une grande variabilité est observée dans la réponse analgésique à l’oxycodone, variabilité pouvant être causée par un polymorphisme génétique. Il est connu que des variations génétiques dans le CYP2D6 compromettent la réponse analgésique à la codéine en rendant moins importante la formation de son métabolite actif, la morphine. Par analogie, plusieurs études supportent l’hypothèse selon laquelle le métabolite oxymorphone, formée par l’isoenzyme CYP2D6, serait responsable de l’analgésie de l’oxycodone. Une déficience génétique de l’enzyme compromettrait la réponse analgésique au médicament. Les travaux effectués dans le cadre de ce mémoire ont démontré que l’inhibition du CYP2D6 chez des sujets volontaires réduit de moitié la production d’oxymorphone, confirmant l’importante implication de l’enzyme dans le métabolisme de l’oxycodone. Ces résultats démontrent une forte ressemblance avec le métabolisme de la codéine, suggérant que l’oxymorphone pourrait être responsable de l’analgésie. Cependant, les travaux effectués n’ont pu établir de relation entre la concentration plasmatique d’oxymorphone et le niveau d’analgésie ressenti par les sujets. La continuation des études sur le mécanisme d’action de l’oxycodone dans la réponse analgésique est essentielle afin d’établir la source des variabilités interindividuelles expérimentées par les patients et ainsi d’éviter des effets secondaires ou lacunes dans le traitement. / Intersubject variability in drug response is an important issue provoking side effects or treatment failure. Such variability may be caused by the decreased activity of the enzyme metabolising the drug, frequently cytochromes P450, a major enzyme system in drug metabolism. These enzymes are prone to genetic mutations called polymorphisms, which alter their metabolic activity. It is therefore important to assess the role of these enzymes to identify their responsibility in the intersubject variability of the drug. Among the important enzyme system that represents the cytochrome P450, CYP2D6 is particularly studied for its genetic polymorphisms, which are of clinical importance. One of CYP2D6 substrates is oxycodone, a narcotic analgesic widely prescribed in clinical practice. A large variability is observed in the analgesic response to oxycodone, which could be caused by genetic polymorphism. It is known that these variations affect the analgesic response to codeine, which form the active metabolite morphine by CYP2D6 to be effective. Several studies support the hypothesis that oxymorphone, a metabolite formed by CYP2D6, has the analgesia properties, in a similar mechanism to codeine. A genetic deficiency in the enzyme would compromise the analgesic response to the drug. Results obtained from our laboratory indicate that inhibition of CYP2D6 halved oxymorphone production, confirming the significant involvement of the enzyme in the metabolism of oxycodone. These results demonstrate a strong resemblance to codeine metabolism, suggesting that oxymorphone may be responsible for analgesia. We could not find a relationship between plasma concentration of oxymorphone and analgesia level experienced by subjects. Studies on oxycodone mecanism of action in the analgesic response should continue to establish the source of intersubject variability experienced by patients and thus avoid side effects or gaps in treatment.

In recent years, tyrosine kinase inhibitors have been widely used for the treatment of certain tumors as so-called targeted therapy. Many studies are concerned with their metabolism and the role of enzymes in the biotransformation process, but very little is known about the impact of tyrosine kinase inhibitors on the expression and activity of biotransformation enzymes. Nevertheless modification of the expression and activity of enzymes may cause adverse interactions of co-administered drugs and their negative impact on the human body. This diploma thesis studies the effect of tyrosine kinase inhibitors vandetanib and lenvatinib and cytotoxic alkaloid ellipticine on biotransformation enzymes in a rat model organism in vivo. The aim was to characterize the effect of the investigated compounds on gene expression, protein expression and activity of cytochromes P450 (CYP) 1A1, 1A2 and 1B1 and flavin-containing monooxygenases FMO1 and FMO3 in renal and hepatic microsomes. Microsomes and RNA were isolated from kidneys of control rats and the pretreated rats. Western blot and immunodetection was used to compare the protein expression levels of studied enzymes in kidney and liver. By reverse transcription, cDNA was prepared from isolated RNA and used as a template for quantitative PCR to compare the...

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Adéla Janoušková Supervisor: RNDr. Jakub Hofman, Ph.D. Title of diploma thesis: Study on impact of selected protein kinase inhibitors on drug resistance mediated by cytochromes P450 Pharmacokinetic drug resistance often leads to failure of an anticancer therapy. One of the mechanisms is increased efflux of drugs from tumour cells, whereas some studies suggest that increased drug conversion to an inactive metabolite might be another contributing mechanism. The aim of this work was to define the possible role of CYP3A4 and CYP2C8 enzymes in the phenomenon of pharmacokinetic resistance and to investigate the possibility of its modulation by new targeted drugs. In the first part, we used the MTT proliferation method together with HepG2 cells stably transduced with particular human enzymes and demonstrated significant involvement of CYP3A4 in docetaxel resistance. In the following part, we examined the inhibitory effects of four selected tyrosine kinase inhibitors on the CYP3A4 activity in intact cells using a commercial kit. Cobimetinib and dabrafenib showed significant inhibitory activity, while osimertinib and brivanib did not. In the final part, we demonstrated the ability of the first two...

Ellipticine is an alkaloid isolated from Apocynaceae plants exhibiting significant antitumor and anti-HIV activities. Cytochromes P450 (CYP) and peroxidases are the enzymes participating in metabolism of ellipticine. This process provides activation and detoxication metabolites of ellipticine. The CYP enzymes, which participate in oxidation of ellipticine in different tissues (liver, lung and kidney) of rat, a model organism simulating the fate of ellipticine in humans have already been identified. In this work, the effects of ellipticine on contents and catalytic activities of CYPs and other components of the mixed-function oxidase (MFO) system in this animal system were studied. For detection of contents of CYPs and other components of the MFO system, spectroscopic and electrochemical methods were used. To determine catalytic activities of CYPs and NADPH:cytochrome P450 reductase, reactions with specific substrates of these enzymes were utilized. The results found in this study demonstrate that expression and catalytic activity of CYP1A is induced by ellipticine in all of the tested organs (liver, kidney and lung) of rats treated with the drug. Moreover in liver, the cytochrome b5 expression is also induced. In addition, in this organ, expression and catalytic activity of CYP3A was increased by...

Le monoxyde d'azote (NO) est formé à partir de L-arginine par la famille des NO synthases. La dysrégulation de la synthèse de cette molécule de signalisation cellulaire est impliquée dans le développement d'un grand nombre de pathologies. Les effets cellulaires du NO sont en partie dus à une inhibition des complexes de la chaîne respiratoire mitochondriale. Nous nous sommes intéressés aux effets du NO sur la régulation de l'oxydation phosphorylante et de le transition de perméabilité, deux processus mitochondriaux gouvernant la survie cellulaire. Nous avons ainsi démontré que l'inhibition de la cytochrome c oxydase (COX) par le NO était associée à une inhibition de la respiration et de la synthèse d'ATP. Cependant le NO augmente l'efficacité de l'oxydation phosphorylante (ATP/O) en diminuant le processus de « slipping ». Toutefois, notre travail a mis en exergue un effet du NO dépendant du substrat utilisé. En présence de NADH seul, le NO n'a pas l'effet bénéfique sur le rendement de l'oxydation phosphorylante, obtenu avec le FADH2 seul ou associé au NADH. L'étude de l'état d'oxydoréduction des cytochromes de la COX a révélé que dans les mitochondries énergisées avec du FADH2 seul ou en association avec le NADH, les cytochromes aa3 sont plus réduits qu'en présence de NADH seul. Nous pouvons suggérer que le « slipping » au niveau de la COX soit dépendant de l'état d'oxydoréduction de ses cytochromes. Le NO pourrait donc être un régulateur physiologique du processus d'oxydation phosphorylante. Nous avons également cherché à étayer l'hypothèse selon laquelle l'inhibition du complexe I aurait un effet anti-apoptotique en inhibant l'ouverture du PTP et la libération de cytochrome c. Le NO ayant un effet sur la chaîne respiratoire dans sa globalité, nous n'avons pu certifier que son effet activateur sur l'ouverture du pore soit dû à l'inhibition d'un complexe en particulier. Il semble que le phénomène de transition de perméabilité soit sensible à l'inhibition du complexe II. L'inhibition du complexe II par un inhibiteur comme le TTFA ou le malonate aurait un effet pro-apoptotique et ce malgré la présence d'inhibiteurs puissants du PTP comme la ciclosporine. Ces résultats suggèrent que le complexe II ferait partie des complexes protéiques régulateurs du PTP et que son inhibition soit dominante sur l'effet induit par l'inhibition du complexe I.

Ce manuscrit résume mes activités de recherche en thèse, dans mes différents séjours post-doctoraux et mes premières années de recherche au Commissariat à l'Energie Atomique. Elles concernent la caractérisation de biomolécules par RMN, comme des sucres, des protéines, dia ou paramagnétiques. Le manuscrit aborde aussi la caractérisation des interactions protéines-eau, du métabolisme cellulaire, et la mesure de vitesses électroniques impliquant des protéines à plusieurs centres d'oxydoréduction. <br />J'aborde ensuite mon travail récent au sein d'une équipe spécialisée dans le xénon hyperpolarisé appliqué à la phase liquide, en particulier la caractérisation de cavités hydrophobes de protéines et la forte complexation du xénon par une famille de molécules-cage nommée cryptophanes.

Studies described in this thesis were at aimed at characterizing the mechanisms involved in the pulmonary carcinogenicity of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), by addressing two critical determinants of carcinogenicity; biotransformation and DNA repair. The contributions of cytochrome P450 (CYP) 2A13 and CYP2A6 to NNK biotransformation in human lung microsomes were investigated. Based on total bioactivation and detoxification of NNK and its keto-reduced metabolite, 4 (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), subjects could be classified as either high or low bioactivators and detoxifiers. Data from all of 29 individuals revealed no correlations between levels of CYP2A mRNA, enzyme activity or immunoinhibition and the degree of total NNK bioactivation or detoxification. However, subgroups were identified for whom CYP2A13 mRNA correlated with total NNK and NNAL bioactivation (n=4) and NNAL detoxification (n=5). Although results do not support CYP2A13 or CYP2A6 as predominant contributors to NNK metabolism in lung of all individuals, CYP2A13 appears to be important in some. The involvement of nucleotide excision repair (NER) in the repair of NNK-induced DNA pyridyloxobutylation was assessed. Extracts from NER-deficient cells were less active at repairing pyridyloxobutyl (POB) adducts on plasmid DNA than were extracts from normal cells, and NER-deficient cells were more susceptible to 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone (NNKOAc)-induced cytotoxicity, demonstrating the participation of NER in the repair of POB-DNA adducts. The role of DNA repair in contributing to inter-organ susceptibility to NNK-induced carcinogenesis was investigated. POB adduct repair was greater in extracts from mouse liver than lung, and activities in lungs of NNK-treated mice were lower than those of saline-treated mice, while repair was 3 times higher in livers of NNK-treated mice relative to control. NNK treatment decreased incision of POB adducts by 92 % in lung extracts and increased incision by 169 % in liver extracts. In addition, NNK altered the levels and binding to POB damage of key incision proteins. These results suggest that lower NER incision activity and NNK-mediated alterations in levels and activities of incision proteins contribute to the relative susceptibility of mouse lung to NNK-induced carcinogenesis. / Thesis (Ph.D, Pharmacology & Toxicology) -- Queen's University, 2008-11-13 14:10:01.603

La variabilité interindividuelle dans la réponse aux médicaments constitue une problématique importante pouvant causer des effets indésirables ou l’échec d’un traitement. Ces variabilités peuvent être causées par une diminution de l’activité de l’enzyme responsable du métabolisme de certains médicaments, fréquemment les cytochromes P450, un système enzymatique majeur dans le métabolisme de ces derniers. Ces enzymes sont sujets à des mutations génétiques appelées polymorphismes, qui altèrent l’activité métabolique. Il est donc important d’évaluer le rôle de ces enzymes dans le métabolisme des médicaments afin d’identifier leur responsabilité dans la variabilité interindividuelle de la réponse au traitement. Parmi l’important système enzymatique que représentent les cytochromes P450, l’isoenzyme CYP2D6 est particulièrement étudiée, ses variations métaboliques revêtant une haute importance clinique. L’un des substrats du CYP2D6 est l’oxycodone, un analgésique narcotique largement prescrit en clinique. Une grande variabilité est observée dans la réponse analgésique à l’oxycodone, variabilité pouvant être causée par un polymorphisme génétique. Il est connu que des variations génétiques dans le CYP2D6 compromettent la réponse analgésique à la codéine en rendant moins importante la formation de son métabolite actif, la morphine. Par analogie, plusieurs études supportent l’hypothèse selon laquelle le métabolite oxymorphone, formée par l’isoenzyme CYP2D6, serait responsable de l’analgésie de l’oxycodone. Une déficience génétique de l’enzyme compromettrait la réponse analgésique au médicament. Les travaux effectués dans le cadre de ce mémoire ont démontré que l’inhibition du CYP2D6 chez des sujets volontaires réduit de moitié la production d’oxymorphone, confirmant l’importante implication de l’enzyme dans le métabolisme de l’oxycodone. Ces résultats démontrent une forte ressemblance avec le métabolisme de la codéine, suggérant que l’oxymorphone pourrait être responsable de l’analgésie. Cependant, les travaux effectués n’ont pu établir de relation entre la concentration plasmatique d’oxymorphone et le niveau d’analgésie ressenti par les sujets. La continuation des études sur le mécanisme d’action de l’oxycodone dans la réponse analgésique est essentielle afin d’établir la source des variabilités interindividuelles expérimentées par les patients et ainsi d’éviter des effets secondaires ou lacunes dans le traitement. / Intersubject variability in drug response is an important issue provoking side effects or treatment failure. Such variability may be caused by the decreased activity of the enzyme metabolising the drug, frequently cytochromes P450, a major enzyme system in drug metabolism. These enzymes are prone to genetic mutations called polymorphisms, which alter their metabolic activity. It is therefore important to assess the role of these enzymes to identify their responsibility in the intersubject variability of the drug. Among the important enzyme system that represents the cytochrome P450, CYP2D6 is particularly studied for its genetic polymorphisms, which are of clinical importance. One of CYP2D6 substrates is oxycodone, a narcotic analgesic widely prescribed in clinical practice. A large variability is observed in the analgesic response to oxycodone, which could be caused by genetic polymorphism. It is known that these variations affect the analgesic response to codeine, which form the active metabolite morphine by CYP2D6 to be effective. Several studies support the hypothesis that oxymorphone, a metabolite formed by CYP2D6, has the analgesia properties, in a similar mechanism to codeine. A genetic deficiency in the enzyme would compromise the analgesic response to the drug. Results obtained from our laboratory indicate that inhibition of CYP2D6 halved oxymorphone production, confirming the significant involvement of the enzyme in the metabolism of oxycodone. These results demonstrate a strong resemblance to codeine metabolism, suggesting that oxymorphone may be responsible for analgesia. We could not find a relationship between plasma concentration of oxymorphone and analgesia level experienced by subjects. Studies on oxycodone mecanism of action in the analgesic response should continue to establish the source of intersubject variability experienced by patients and thus avoid side effects or gaps in treatment.

Microbial chlorate respiration plays an important role in the turnover of oxochlorates in nature and industrial waste management. This thesis deals with the characterization of the molecular components of chlorate respiration in Ideonella dechloratans. Chlorate respiration utilizes two soluble periplasmic enzymes, chlorate reductase and chlorite dismutase, to convert chlorate to chloride and oxygen. The genes encoding the enzymes participating in the chlorate degradation have been sequenced, and are found in close proximity, forming a gene cluster for chlorate metabolism. This work also includes the successful recombinant expression of three genes from Ideonella dechloratans. Two of the gene products, chlorite dismutase and the C subunit of chlorate reductase, participate in the chlorate respiration. The third gene, which is found close to the gene cluster for chlorate metabolism, encodes a soluble c-type cytochrome. The localization of the gene suggests the corresponding protein as a candidate for a role as electron donor to chlorate reductase. Also, the role of soluble periplasmic c cytochromes of Ideonella dechloratans in chlorate respiration was studied. At least one of the soluble c cytochromes was found capable of serving as electron donor for chlorate reduction. This c cytochrome, and several others, can also donate electrons to a terminal oxidase for subsequent reduction of oxygen, as required for the branched electron flow during chlorate respiration.